Core Insights - Allarity Therapeutics has signed a new commercial agreement with a non-disclosed EU-based biotechnology company, granting a non-exclusive global license to selected proprietary Drug Response Predictor (DRP) algorithms in breast cancer, along with laboratory services from Allarity's Medical Laboratory in Denmark [1][2] Group 1: Agreement Details - The agreement includes advanced transcriptome analysis services to support the partner's precision oncology solutions in breast cancer and secures purchase commitments for Allarity's laboratory services over the next year [2] - The financial impact of this agreement on Allarity's outlook is not expected to be significant [2] Group 2: Technology and Expertise - The agreement validates the broad applicability of Allarity's DRP technology, which is based on decades of research and development, aimed at improving patient selection and treatment outcomes [3] - Allarity's DRP platform utilizes advanced gene expression profiling to predict individual tumor responses to specific therapies, covering over 100 drugs, including investigational compounds and approved drugs [3][5] Group 3: Product Information - Stenoparib, developed by Allarity, is a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential as a therapeutic for various cancers, including ovarian cancer [4] - The company holds exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [4][6] Group 4: Company Overview - Allarity Therapeutics is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly through the use of its DRP technology for selecting patients who may benefit most from stenoparib [6]

LinkedIn: https://www.linkedin.com/company/allaritytx/ TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced the Company's CEO, Thomas Jensen, will deliver a company overview focused on stenoparib and the Company's DRP companion diagnostic platform and conduct one-on-one meetings at the Pharma Partne ...